anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Simple limbal epithelial transplantation (SLET) was introduced in 2012 by Sangwan and coworkers to overcome the issues mainly related to the cost of a GMP-certified product and ease of surgical manipulations that al- lows use of smaller pieces of limbus from the contralateral eye (thus avoiding iatrogenic problems). A completely epithelialized, avascular and stable corneal surface was achieved by 6 weeks and was maintained in all recipient eyes at a mean follow-up of 9.2 ± 1.9 months. Best corrected visual acuity improved from worse than 20/200 in all recipient eyes before surgery to 20/40 or better in four (66.6%) eyes. None of the donor eyes developed any complications.Basu et al. reported autologous SLET on a population of 125 patients which included 65 adults and 60 children suffering from unilateral LSCD. 76% (95/125) of eyes maintained a successful outcome at final follow-up without progressive conjunctivalization, development of persistent epithelial defect, infection, or need for repeat SLET. Survival probability of 80% in adults and 72% in children after 1 year. So far, most of the reports have been about autoSLET, that is, the limbal explants are obtained from the unaffected eye of the same recipient, avoiding immune reaction at the later stage. Also, they demonstrated SLET had promising result both in adults and children. A study by Iyer and coworkers used alloSLET in early stages after ocular chemical injury to achieve rapid epithelialization. Instead of taking the biopsy from the recipient's healthy eye, they took it from a cadaveric donor and performed the SLET. Epithelialization and improved best corrected visual acuity and corneal phenotype were achieved at early stages; however, 7 of 18 eyes had a gradual failure of the allograft, and 5 eyes underwent subsequent limbal autograft. Symblepheron formation involving one to two quadrants was recorded in 3 eyes (16.7%). Visual rehabilitative procedures in the chronic phase of chemical injury, in most instances after alloSLET in the acute stage, did not require any keratoplasties. Unfortunately, most diseases causing limbal deficiency, e.g., surface burns (alkali/ thermal), Stevens-Johnson syndrome, contact lens-related epitheliopathy, and ocular cicatricial pemphigoid, tend to affect both eyes of a patient. Autologous SLET may not be applicable in patients with bilateral eyes involvement. In this study, the effect of allogeneic SLET will be investigated.
1300422 Fungus INDIAN DRUGS RESEARCH ASSOCIATION 24 March 1970 [28 March 1969] 14187/70 Heading C6F [Also in Division A5] The fungus Phomopsis paspali (ATCC 20244) is cultivated in a nutrient medium for 15-20 days at a temperature of 20-25‹C, thereafter the fungus and/or nutrient medium is/are extracted with one or more organic solvents such as ethyl alcohol, methyl alcohol, chloroform, ether or benzene, and the solvent is evaporated from the extract under reduced pressure to yield a dried product. The ethanol-soluble extract is about 85% soluble in water at room temperature, contains no sulphur when submitted to sodium fusion test and results in no increase of sugar content when submitted to acidic hydrolysis. The product induced tranquility, sedation and fine tremors in mice, rats, and dogs, reduced the body temperature of these animals and potentiated the hypnotic action of hexobarbitone. The ether extract of the ethanol extract contains no alkaloids or glycosides, gives a strongly positive Liebermann-Burchard reaction and exhibits three well-defined spots in thinlayer chromatography on silica gel using chloroform: methanol (95:5) as solvent and vanillin in 50% phosphoric acid as developing agent. The solvent extracts may be extracted with ether, petroleum ether or chloroform and the resulting solution dried. Components in the dried products may be chromatographed on alumina and eluted with petroleum ether, benzene and chloroform. It is stated that the biologically interesting fraction is obtained only in the chloroform eluate. The active products may be compounded with therepeutically-compatible solid or liquid carriers.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to medicine, in particular, to gynecology and can be applied for treatment of precancerous diseases of uterus neck. Medicine is made in form of vaginal suppository, containing recombinant composition of proteins E7 of human papilloma virus of 16 and 18 types, bound with amino acid by sequence of heat sock protein m.m. 70 kDa from M. tuberculosis, hydrophobic base, polyethylene glycol 1500, polyethylene glycol 400, preservative, chitosan with degree of deacetylation 86%. ^ EFFECT: invention ensures stability of recombinant proteins, included into its composition, during long time. ^ 1 tbl, 4 ex
The invention relates to a cosmetic cleansing and skin care preparation which is particularly suitable for extremely greasy pubertal skin and exhibits very good sebostatic effectiveness. The preparation contains 0.25-5 wt. % of a combination comprising 5-40 wt. % of an alga laminaria saccharina extract; 10-60 wt. % of lilium candidum root extract; 10-50 wt. % glycyrrehetinic acid as a natural extract of glycyrrhiza glabra. The preparation also contains 99.75 to 95 wt. % cosmetic auxiliary agents and carriers, optionally mixed with additional active substances.
PROBLEM TO BE SOLVED: To provide a peptide which has a relatively low mol.wt. and can be used for preventing and treating diseases accompanied of the abnormal production of IL-6. SOLUTION: This IL-6 signal transmission-antagonizing peptide has the following characteristics. (1) The IL-6 signal transmission-antagonizing peptide bound to an IL-6 receptor exhibits an IL-6 function-inhibiting action on the three- dimensional structure. (2) The basic primary structure of the specific three- dimensional structure formation contains a 6 to 9 amino acid sequence whose both ends are nipped with cysteine molecules. (3) The amino acid sequence has a mol.wt. of <=3 kd. The IL-6 signal transmission-antagonizing peptide is an IL-6-binding motif peptide having a human IL-6 signaling-inhibiting action against the human IL-6 receptor.
Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab 250 mg/m2 weekly. No comparison between arms was planned.
The United Nations Multiple Micronutrient Preparation (UNIMMAP) supplement is a capsule containing 15 micronutrients (vitamins A, D, E, B1, B2, B6, B12, C, Niacin, Folic Acid, Fe, Zn, Cu, I, Se) at the Recommended Daily Allowance level. UNIMMAP will be provided in capsule form and taken daily with water for 12 weeks.
BACKGROUND: Low back pain (LBP) is a common condition causing disability and high healthcare costs. Alberta faces challenges with unnecessary referrals to specialists and long wait times. A province-wide standardized clinical care pathway based on evidence-based best practices can improve efficiency, reduce wait times, and enhance patient outcomes. Implementing such pathways has shown success in other areas of healthcare in Alberta. This study developed a clinical decision-making pathway to standardize care and minimize uncertainty in assessment, diagnosis, and management.
METHODS: A systematic rapid review identified existing tools and evidence that could support a comprehensive LBP clinical decision-making tool. Forty-seven healthcare professionals participated in four rounds of a modified Delphi approach to reach consensus on the assessment, diagnosis, and management of patients presenting to primary care with LBP in Alberta, Canada. This project was a collaborative effort between Alberta Health Services' Bone and Joint Health Strategic Clinical Network (BJHSCN) and the Alberta Bone and Joint Health Institute (ABJHI).
RESULTS: A province-wide expert panel consisting of professionals from different health disciplines and regions collaborated to develop an LBP clinical decision-making tool. This tool presents clinical care pathways for acute, subacute, and chronic LBP. It also provides guidance for history-taking, physical examination, patient education, and management.
CONCLUSIONS: This clinical decision-making tool will help to standardize care, provide guidance on the diagnosis and management of LBP, and assist in clinical decision-making for primary care providers in both public and private sectors.
Subjects will be referred for supervised exercise therapy. Subjects will have 3 visits per week for 12 weeks. Each visit will include a minimum of 30 to 40 minutes of exercise to improve ambulation with a certified trainer.
A total of 240 sites with deep pocket in 30 systemically healthy patients with chronic periodontitis, from subjects attending Jordan University of Science and Technology (JUST) Postgraduate Dental Clinic (PDC), the age range were (28-55) year, between Apr 2017 and Oct 2017. Those patients were enrolled in a randomized controlled single-blinded study. For each patient, full medical and dental history and periodontal examination were recorded. Clinical parameters such as pocket depth (PD), clinical attachment loss (CAL), gingival index (GI) and plaque index (PI) were evaluated at the baseline. All Patients underwent initial periodontal therapy; SRP which was performed using a sonic device and hand instruments and the sites were divided randomly into two groups SRP alone and SRP with adjunctive diode 810 nm laser in the contralateral sites in the same jaw. The Clinical parameters have been re-evaluated at 1, 3 and 6 months to test the effectiveness of (810 nm, 2 W, pulsed mode, for 20 sec) in treatment of CP. Diode laser therapy was applied to periodontal pockets in the same day of treatment.
FIELD: medicine. SUBSTANCE: method involves applying complex drug therapy including antibiotics, immunostimulating and disintoxicating preparations as background treatment and intravenous laser radiation treatment of blood at 630 nm wavelength with 1 mW power released at the light guide end and 40 min exposition time. Then one day later, laser radiation at 830 nm wavelength with 3 mW power released at the light guide end and 5 min exposition time is applied. 4-5 sessions are administered to prevent complications beginning from the first day the patient is admitted. 8-10 sessions are administered as medical treatment from the moment purulent septic fever appears, until body temperature comes to normal state. EFFECT: enhanced effectiveness of treatment.
The invention discloses an acetylspiramycin slow-release tablet and a preparation method. The acetylspiramycin slow-release tablet comprises the following components in parts by weight: 30-40 parts of acetylspiramycin, 10-20 parts of magnesium alginate, 20-25 parts of ethyl cellulose, 10-20 parts of compressible starch, 15-20 parts of dextrin, 0.5-1 part of polyoxyethylene aliphatic alcohol ether and 0.5-1 part of superfine silica powder. The preparation method comprises the following steps: preparing the components, granulating, drying, shaping the tablet, and pressing the tablet. By adopting the acetylspiramycin slow-release tablet, acetylspiramycin can be slowly released for a long time in bodies, and the blood concentration is stable and small in fluctuation, so that the administration frequency can be reduced, and the patient compliance can be improved. The medicine effect can be maintained by controlling the concentration of the medicine in blood, the times of medicine release peaks can be reduced, and organs of patients can be also certainly protected. The acetylspiramycin slow-release tablet is simple in process, good in reproducibility, easy in industrial production, low in cost and beneficial for product price reduction.
The present invention discloses a medicine for treating osteomyelitis and a preparation method of the medicine. According to a secret recipe handed down from generation and basic theories of traditional Chinese medicines, the present invention is prepared from various rare traditional Chinese medicines through a modern scientific and technical process and has the effect of kidney invigoration, spleen strengthening, detoxification, granulation promotion, blood circulation promotion and blood stasis removal. The medicine for treating the osteomyelitis has the advantages of treatment specificity, convenient and simple taking, rapidness and long-term efficiency without any side effect. Due to years of clinical repeated practice, the present invention is capable of effectively treating bone diseases and osteoarthropathy and rapidly eliminating pain and has comparatively obvious effect on improving endocrine unbalance of human bodies. By the medicine for treating the osteomyelitis, a surgical method without operations can be obtained therapeutically; the medicine has peculiar medicine effect and has reliable therapeutic effect through effect observation. Oral therapeutic medicines for the osteomyelitis are rare in markets at home and abroad; thereby, the medicine for treating the osteomyelitis has broad prospects and has huge and; economic and social benefits.
Background: Blood transfusion has advanced toward component therapy for specific requirements during trauma and surgery. Oxidative stress is induced in erythrocytes during storage. Hence, antioxidants as additives can be employed to counteract oxidative stress and enhance antioxidant defenses. Therefore, this study investigates the combinatorial effects of vitamin C and l-carnitine on erythrocytes during storage. Methodology: Erythrocyte samples were categorized into control and experimental groups-vitamin C (10 mM) and l-carnitine (10 mM) and stored under blood bank conditions (at 4°C) for 35 days. Hemoglobin (Hb), antioxidant enzymes (superoxide dismutase [SOD], catalase [CAT] and glutathione peroxidase [GPX]), lipid peroxidation products (conjugate dienes and thiobarbituric acid reactive substances [TBARSs]), protein oxidation products, metabolic markers (glucose, lactate dehydrogenase), glutathione (GSH), superoxides, and hemolysis were assessed at weekly intervals. Results: SOD activity increased on day 7 in the controls, whereas it increased on days 7 and 14 in the experimental groups. CAT activity increased on day 35 in both the groups. GPX activity increased on day 7 in the controls. Hb levels decreased on days 14 and 35 in the controls and on day 35 in the experimental groups. Hemolysis increased from day 7 onward in both the groups. Protein oxidation products were maintained throughout the storage. GSH levels increased on day 21 in the controls and on days 14 and 21 in the experimental groups. Superoxides and conjugate dienes decreased from day 14 in both the groups. TBARSs decreased on day 7 in the experimental groups. Conclusion: Vitamin C and l-carnitine have synergistically enhanced the efficacy of stored erythrocytes in terms of Hb, antioxidant enzymes, and lipid peroxidation.
The invention relates to a flavonoid compound which is extracted from ciliate desert-grass and has the action of resisting prostatic cancers in vitro and a preparation method thereof. The preparation method comprises the following steps of: extracting from the ciliate desert-grass by using ethanol, extracting firstly by using petroleum ether after carrying out decompressed concentration, then extracting by using ethyl acetate, carrying out decompressed concentration on the extraction liquid of the ethyl acetate, separating out flavone by the purifying treatment of concentrated liquid and carrying out vacuum drying at low temperature so as to obtain ciliate desert-grass flavone powder. The apoptosis experiment of prostatic PC-3 cancer cells in vitro is carried out on the flavone powder. An experimental result shows that the flavone has an obvious suppressing action to the PC-3 cancer cells of the prostatic cancers; and moreover, the flavone has an obvious dose-effect relationship. Fluorescence analysis shows that the flavone has an obvious suppressing action to the activity of a transcription factor NF-kappa B. The flavonoid compound and the preparation method thereof also have the advantages that resources are abundant, equipment is simple and convenient, the extraction rate of a product is high, and a solvent can be recovered. Therefore, the flavonoid compound has favorable development prospect of medicinal and functional foods.
PURPOSE:A hair growing agent, containing elastase well known as a remedy for hyperlipemia and arteriosclerosis as an active constituent, and having hair production promoting action and hair growth action and further depilation preventing action. CONSTITUTION:An elastase hair tonic containing elastase. The elastase is an enzyme extracted industrially from pig liver, and having 25,900mol weight. The elastase has hitherto been applied to hyperlipemia, arteriosclerosis, hypertension, etc., but is recently found to be useful as a hair growing agent. Thus, the elastase is capable of promoting the hair production, promoting the growth of the produced hair, and suppressing the degeneration and depilation in the early stage. Particularly, the effect is rapid in the coating administration. The amount of the elastase to be incorporated is preferably 0.05-0.2wt./vol%.
Patients received the test group RC18 160mg weekly administered subcutaneously for 48 times.Starting with the forty-ninth dose,the trial went into the open phase . All participants were treated with the test drugs.
Forty-seven women in treatment in the outpatient clinic of the Rheumatology Division of State University of Campinas(UNICAMP) who met the inclusion criteria for this study (being female with osteoporosis and aged 60 or above) were assigned, at random, to wear ethyl-vinyl-acetate insoles with medial arch supports and metatarsal pads over a four-week period. Balance, using the Berg Balance Scale (BBS) and the Timed Up and Go (TUG) indexes; pain, using a numeric pain scale (NPS); and disability of the feet, using the Manchester Foot Pain and Disability Index (MFPDI), were assessed at baseline and after four weeks.
The subject is to manufacture molding with core efficiently and at one time from molding material such as powder granule. To this end, a method for manufacturing molding with core was invented, which method uses compression molding means, that comprise a die, and upper and lower punches, where at least the upper punch, preferably both the upper and lower punches, have a double structure consisting of a central punch and an outer punch surrounding the outer periphery of the central punch, both the central punch and the outer punch being capable of performing sliding motions as well as compressing operations. This method includes steps of separate supplying of molding materials for core and molding material for outer layer, a compression molding step of the molding material for core and/or the molding material for outer layer, and a compression molding step of the whole molding with core. The invention also provides a rotary compression molding machine, used for execution of the method. The invention also provides various characteristic molding with core manufactured by the above manufacturing method. The core may include a large amount of microcapsules which are incomplete molding, or plural cores.
MyChart message subjects with high A1C blood tests to help manage their diabetes and prevent some of the complications caused by high sugars. The message recommends that they schedule a visit with their doctor who can recheck the blood test and help get their diabetes under control.
Systems and methods generally useful in medicine, cellular biology, nanotechnology, and cell culturing are discussed. In particular, at least in some embodiments, systems and methods for magnetic guidance and patterning of cells and materials are discussed. Some specific applications of these systems and methods may include levitated culturing of cells away from a surface, making and manipulating patterns of levitated cells, and patterning culturing of cells on a surface. Specifically, a method of culturing cells is presented. The method may comprise providing a plurality of cells, providing a magnetic field, and levitating at least some of the plurality of cells in the magnetic field, wherein the plurality of cells comprise magnetic nanoparticles. The method may also comprise maintaining the levitation for a time sufficient to permit cell growth to form an assembly.
Zytiga (reference abiraterone acetate formulation, hereafter referred to as R-AA) administered once daily as (2 x 500mg Zytiga tablets) + Prednisone (5mg once or twice daily, depending on prostate cancer population). R-AA administered once daily either ≥ 1 hour before or ≥ 2 hours after a meal. Patients treated for 84 days.
Forced Vital Capacity (FVC), Forced Expiratory Volume in the First Second (FEV1), FEV1/FVC, Heart Rate Variability (HRV), airway resistance (kPa/l/s), before and after an 11 minutes, one-session, guided relaxation technique Following 30-40 minutes questionnaire, 5 minutes heart rate (HR) and oxygen saturation (SpO2) recording, 11 minutes relaxation technique (listening via headphone to audio recording. In the meanwhile, heart rate and saturation are recording) to be completed by second heart rate (HR) and oxygen saturation (SpO2) recording. Entire procedure 60-80 minutes.